Insulin gene therapy requires that insulin secretion be coupled to metabolic requirements. To this end, we have developed an insulin transgene whose transcription is stimulated by glucose and inhibited by insulin. Glucose-and insulin-sensitive promoters were constructed by inserting glucose-responsive elements (GlREs) from the rat L-pyruvate kinase (L-PK) gene into the insulin-sensitive, liver-specific, rat insulin-like growth factor binding protein-1 (IGFBP-1) promoter. Glucose (5 to 25 mM) stimulated, and insulin (10 −10 to 10 −7 M) inhibited, luciferase expression driven by these promoters in primary cultured rat hepatocytes. The capacity of transfected hepatocytes to secrete mature, biologically active insulin was demonstrated using a human proinsulin cDNA (2xfur), modified to allow protein processing by endogenous endopeptidase activity. Medium conditioned by insulin-producing hepatocytes contained greater than 300 U/ml immunoreactive insulin, while denaturing SDS-PAGE of an anti-insulin immunoprecipitate revealed bands
Introduction
Diseases caused by a single protein deficiency are logical targets for gene replacement therapy. Animal studies suggest gene therapy may become therapeutic for a number of such metabolic diseases. [1] [2] [3] [4] [5] Diabetes mellitus is a candidate for gene therapy, since it is caused by deficient production of a single protein, insulin. Yet, the limited capacity of non-␤ cells to process proinsulin and, more importantly, the necessity of coupling circulating insulin levels to metabolic demand have delayed development of a clinically applicable model.
Few tissues can provide the post-translational processing required to convert proinsulin into insulin. Given the diminished hormonal activity of proinsulin, 6 gene therapy applications utilizing proinsulin would require a 10-fold greater transgene synthesis, than if mature insulin were produced. Select non-␤ cells are able to process proinsulin, presumably due to the action of nonspecific endogenous proteinases. 7 However, in unmodified cells only limited quantities of the proinsulin transgene pro-with the mobilities of insulin A, and B chains. Biological activity of hepatocyte-produced insulin was demonstrated in a transfection assay, in which medium conditioned by insulin-producing hepatocytes exerted an effect similar to 10
insulin. We then combined the glucose-and insulin-sensitive promoter with the modified human proinsulin cDNA to create a metabolically sensitive insulin transgene ((GlRE) 3 BP-1 2xfur). In both H4IIE hepatoma cells stably transfected with this construct, and normal rat hepatocytes (GlRE) 3 BP-1 2xfur-mediated insulin secretion increased in response to stimulation by glucose. Moreover, a capacity to decrease insulin production in response to diminishing glucose exposure was also demonstrated. We conclude that the transcriptional regulation of insulin production using these glucose-and insulin-sensitive constructs meets the requirements for application in a rodent model of insulin gene therapy. Gene Therapy (2000) 7, 205-214.
duct is converted to insulin. 8 Alternatively, minimal modification of the human insulin cDNA allows translation of a proinsulin gene product whose B-C and C-A junctions encode recognition sites for a ubiquitous endopeptidase, furin. 9 Transient transfection of this modified human insulin cDNA into either a human kidney (HEK293) or a myoblast cell line allows production of mature, biologically active human insulin. 9, 10 The utility of this approach was recently confirmed in vitro utilizing hepatocytes in primary culture, 11 and by Muzzin et al 12 who dramatically improved the efficacy of liver-based insulin secretion in vivo by applying a rat insulin-1 transgene modified to allow cleavage by endogenous proteases.
A greater impediment to successful insulin gene therapy has been difficulty coupling circulating insulin levels to serum glucose concentrations. The clinical benefits of re-establishing glucose-responsive insulin production have been demonstrated in human models of isolated islet transplantation 13 and whole pancreas transplantation. 14 However, a mechanism to obtain glucose-dependent insulin production has been absent from published models of isolated gene transfer. 12, [15] [16] [17] [18] [19] In pursuit of a functional gene transfer approach, we designed a system of glucose-and insulin-sensitive gene transcription to regulate insulin production. We inserted carbohydrate-responsive elements from the rat liverpyruvate kinase (L-PK) gene into the insulin-suppressive basal promoter of the rat insulin-like growth factor binding protein-1 (rIGFBP-1) gene to produce a promoter that is active in hepatocytes, inhibited by insulin and stimulated by glucose. In separate studies of a modified human proinsulin cDNA sensitive to processing by the ubiquitous endopeptidase furin, we determined the capacity of rat hepatocytes in primary culture to secrete mature human insulin. Finally, we coupled the glucose-and insulin-sensitive promoter to the modified human proinsulin expression sequence, and demonstrated glucosestimulated human insulin secretion from primary rat hepatocytes. Our construct appears to contain all the components required to implement an expandable rat model of insulin gene therapy.
Results
Response of p(GlRE) n BP-1Luc constructs to glucose and insulin We constructed a family of promoters, which are active in hepatocytes, stimulated by glucose, and inhibited by insulin. The glucose-response element (GlRE) of the rat L-PK gene was inserted directly upstream of the insulinsensitive element of the rat IGFBP-1 (BP-1) basal promoter 20 ( Figure 1 ). These promoter constructs, inserted into a luciferase expression vector, vary with respect to the number of GlRE sequences present, and their orientation. In p(GlRE) 1 BP-1Luc and p(GlRE) 4 BP-1Luc the L-PK sequences remain in their native orientation, whereas they are reversed in p(GlRE) 2 BP-1Luc and p(GlRE) 3 1Luc. Within each construct all GlRE sequences share the same orientation.
As a first evaluation of the transcriptional activity of our constructs, we tested the response of a representative promoter to both insulin and glucose in vitro (Figure 2 ). Hepatocytes in primary culture transfected with p(GlRE) 2 BP-1Luc, and pCMV␤gal as a control for transfection efficiency, were incubated in either 10 −10 m or 10 −7 m insulin; concentrations known to span the range of insulin inhibitory effects with respect to the IGFBP-1 promoter in vitro. 20 When cells were provided lactate (10 mm), which does not stimulate the GlRE, 21 promoter activity was suppressed approximately 60% in the presence of 10 −7 m insulin, indicating function of the insulinresponse region (IRR) within the IGFBP-1 promoter. Replacing lactate with increasing amounts of glucose resulted in a three-fold increase in promoter activity, indicating function of the L-PK-derived glucose response elements. Each of the (GlRE) n BP-1Luc constructs was inhibited by insulin and stimulated by glucose (data not shown). Glucose concentrations were chosen to span the normal range in both humans (75-140 mg/dl) 22 and rats (110-387 mg/dl). 23 The fact that glucose increased expression in the face of an inhibitory concentration of insulin (10 −7 m) demonstrates that GlRE-mediated stimulation is not subordinate to suppression by insulin.
Glucose dose-response studies were performed for each of the four promoters to determine if the number of GlREs present affect the magnitude or kinetics of the response. Primary hepatocytes were cotransfected with the p(GlRE) n BP-1Luc constructs, and supplied with either lactate or increasing concentrations of glucose during an overnight incubation. Increasing glucose concentrations induced a progressive increase in normalized reporter activity for each of the constructs in the presence of 10 −7 m insulin ( Figure 3 ). While the presence of a single glucose-response element was sufficient to induce a statistically significant glucose response, the magnitude of this response increased with the copy number of GlREs. In this series of experiments, exposing cells to 25 mm glucose stimulated expression to levels ranging from 1.6-fold Figure 2 Glucose responsiveness of p(GlRE) 2 for p(GlRE) 1 BP-1Luc to a maximum of 6.4-fold for p(GlRE) 3 BP-1Luc, when compared with baseline. In contrast to the variability in maximal stimulation, all constructs appeared to share a similar sensitivity to glucose and responded across the tested range of 5-25 mm.
The increased expression observed following exposure to glucose is presumably due to transcriptional stimulation mediated by the GlRE. However, a glucosedependent mechanism that diminishes insulin-mediated inhibition might produce similar results. To distinguish between GlRE-mediated stimulation and inhibition of the insulin-response region, hepatocytes transfected with p(GlRE) 2 BP-1Luc were treated with increasing amounts of insulin (10 −11 to 10 −6 m) and supplied with either 10 mm lactate or 25 mm glucose as a carbohydrate source (Figure 4) . At all insulin concentrations reporter activity Figure 4 Comparison of insulin dose-response curves for p(GlRE) 2 Gene Therapy was two-to three-fold greater in cells exposed to glucose than in cells provided lactate. Moreover, the proportional increase in activity induced by glucose was similar across the entire range of insulin concentrations. As determined from the plotted data, the insulin concentration associated with a 50% inhibition of activity (IC 50 ) was approximately 10 −9 m.
Time-course of p(GlRE) 3 BP-1Luc response to glucose Time-course experiments were performed to determine the kinetics of glucose-stimulated expression of a transgene protein. Hepatocytes were transfected with p(GlRE) 4 BP-1Luc and cultured in glucose-free medium for 24 h in the presence of 10 −7 m insulin. Medium was replaced with glucose-containing medium (25 mm) at time 0, and cells were harvested at the times indicated. Following exposure to glucose, an increase in the quantity of transgene protein product could be detected in cells transfected with p(GlRE) 4 BP-1Luc in as little as 1 h, with a progressive increase over the 10 h period examined ( Figure 5 ).
Production of mature human insulin in rat hepatocytes by a modified proinsulin construct Excision of C-peptide from translated proinsulin is a function normally restricted to tissues that express the requisite specific endopeptidases, prohormone convertase-1/3 and prohormone convertase-2. 24 To enable hepatocytes to process proinsulin to insulin, we obtained a human proinsulin cDNA (2xfur), 9 modified to allow Cpeptide excision by furin, a protease expressed in many tissues including hepatocytes. 25 Following construction of a CMV promoter-driven plasmid incorporating the 2xfur sequence (pCMV2xfur), we transfected hepatocytes, and metabolically labeled nascent cellular proteins with 35 Smethionine/cysteine. Electrophoresis, under reducing and denaturing conditions, of anti-insulin immunoprecipitates from both cell lysates and conditioned medium revealed a band whose intensity increased between 4 and Figure 5 Time-course of (GlRE) 4 24 h ( Figure 6 ). With an apparent molecular weight of 9.8 kDa the band's extrapolated size is greater than either the insulin A-or B-chain in combination with the C-peptide, but similar to the 9 kDa determined for human proinsulin expressed from the same construct in myoblasts. 10 In medium conditioned for 24 h, immunoprecipitated bands with mobilities identical to the B-and A-chains of insulin are present ( Figure 6 ), confirming that the insulin transgene product is processed into mature insulin, and that mature insulin is secreted into the culture medium. Independent experiments performed using nontransfected cells failed to reveal the three bands corresponding to insulin products (data not shown).
Medium conditioned by hepatocytes transfected with pCMV2xfur and then assayed for human insulin provides an estimation of the capacity of hepatocytes to produce human insulin. After transfection with 1, 5 or 10 g pCMV2xfur/60 mm plate, hepatocytes were washed twice in PBS and cultured overnight in serum and insulin-free medium. Enzyme immunoassay of medium conditioned by nontransfected cells demonstrated undetectable levels of immunoactivity. In contrast, medium conditioned by transfected cells produced levels of insulin immunoactivity greater than 10-fold the concentration in fasting human serum (5-20 U/ml) 22 ( Figure 7 ). The detection of insulin immunoactivity in an assay possessing minimal cross-reactivity with pro-insulin (0.005%, Abbot Diagnostics) provides further evidence of successful proinsulin processing by hepatocytes.
We confirmed the biological activity of our transgene product by testing the capacity of secreted insulin to inhibit insulin-sensitive reporter gene expression in a transient transfection assay. Primary cultured hepatocytes were cotransfected with pCMV␤gal, and p − 324-+ 96BP-1Luc, an insulin suppressible luciferase expression vector driven by the rIGFBP-1 promoter. Cells were cultured overnight in serum-free medium containing 10 −7 m insulin. Control cells were provided serum-free medium, which had been conditioned overnight by nontransfected hepatocytes, and to which insulin had been added at a concentration of either 0, 10 −7 or 10 −9 m. Test cells were supplied medium conditioned overnight by hepatocytes transfected with pCMV2xfur (5 g/60 mm plate), and all cells were harvested for luciferase and ␤-galactosidase assay following a further overnight incubation. As expected, compared with 10 −9 m insulin, exposure to (Figure 8 ). More significantly, pCMV2xfur conditioned demium also inhibited expression, and the degree of inhibition was consistent with an insulin effect in the conditioned medium on the approximate order of magnitude of 10 −7 m insulin.
Glucose-stimulated human insulin production in rat hepatocytes We then determined if a glucose-and insulin-sensitive promoter could mediate glucose-responsive insulin production from hepatocytes. We first created a glucoseresponsive insulin transgene, (GlRE) 3 BP-1 2xfur, by replacing the luciferase sequence in p(GlRE) 3 BP-1Luc with the 2xfur proinsulin sequence. To verify that glucose stimulation occurred at the level of transcription, we performed Northern analysis of primary hepatocytes infected with an adenovirus containing the (GlRE) 3 BP-1 2xfur sequence. Total RNA was isolated from transduced cells cultured overnight in serum-and insulin-free medium containing either lactate (10 mm) or varying concentrations of glucose (5-25 mm). Membranes were sequentially probed for human insulin and GAPDH, and the degree of glucose-stimulated insulin expression determined by dividing lane-specific densitometry measurements for insulin by readings obtained for GAPDH ( Figure 9 ). Adding glucose to the medium increased insulin expression relative to cells exposed to lactate alone (P Ͻ 0.05), while increasing glucose from 5 to either 10 or 25 mm stimulated insulin expression still further (P Ͻ 0.05). Hepatocyte insulin production also increased in response to glucose. Following transfection with p(GlRE) 3 BP-1 2xfur primary hepatocytes were again provided lactate or varying amounts of glucose ( Figure 10 ). Insulin immunoactivity was detected in the conditioned medium of nontransfected cells; possibly carried over from incubation with insulin-containing medium. How- ever, medium conditioned by cells transfected with the insulin transgene demonstrated a four-fold increase in the amount of immunoreactive insulin, even in the absence of glucose. Substituting glucose for lactate in the culture medium stimulated a further dose-dependent increase in insulin secretion. The RIA used in these analyses is reported to have minimal cross-reactivity with proinsulin (Ͻ0.2%), supporting the conclusion that p(GlRE) 3 BP-1 2xfur is able to mediate glucose-responsive human insulin secretion from rat hepatocytes in primary culture.
Diminishing transgene expression following transient transfection, and the limited longevity of hepatocytes in primary culture, complicate analysis of extended timecourse studies. To overcome these obstacles, and confirm the reversibility of glucose-stimulated insulin secretion, we created an insulin-secreting hepatoma cell line by stably transfecting H4IIE cells with p(GlRE) 3 BP-1 2xfur. An insulin-secreting clone, A3, was chosen for further study, and cultured in two groups of triplicate plates in serum-and insulin-free medium. The first group initially received lactate-containing medium, while the second group initially received glucose-containing medium. Each group then alternately received two periods of exposure to glucose and two exposures to lactate. Assay by human insulin-specific RIA of conditioned medium collected after 2 days in each culture condition indicated that A3 cells continuously secreted small amounts of insulin under glucose-free conditions (5-10 U/ml) ( Figure 11 ). However, insulin levels in the culture medium were significantly greater during each period of glucose exposure (21-38 U/ml). Moreover, insulin secretion returned toward baseline upon glucose withdrawal, confirming the reversibility of glucose stimulation in this model. Increased insulin secretion following re-challenge with glucose indicates that reduced insulin secretion following glucose withdrawal was not diminished due to reduced cell viability. The order of exposure is also irrelevant, as insulin secretion increased in response to glucose irrespective of whether cells were exposed first to glucose or first to lactate.
Discussion
Our results demonstrate that a metabolically sensitive promoter driving expression of a modified proinsulin cDNA can regulate human insulin secretion from hepatocytes in response to glucose exposure. By inserting multimers of the rat L-PK glucose-responsive element into the insulin-sensitive IGFBP-1 basal promoter we created a family of promoters whose activity is stimulated by glucose and inhibited by insulin. Because our chimeric promoter/enhancer constructs are novel, we chose to verify the efficacy of individual promoter elements. The results of transient transfection experiments confirm that the GlRE, the IGFBP-1 basal promoter, and its IRR, each remain functional. Exposing transfected cells to glucose produces a dose-dependent increase in reporter gene expression at all insulin concentrations (Figures 2, 3 and  4) . While glucose treatment of hepatocytes could be argued to increase gene expression in a nonspecific manner, glucose stimulation of our promoters remains significant when expression is controlled for by cotransfected ␤-galactosidase activity. With respect to the IRR, insulin inhibits expression of a representative promoter in both the presence and absence of glucose (Figure 4) . These findings appear to exclude the possibility that glucose exposure merely interferes with the suppressive effects of insulin, and are consistent with the fact that such an effect is also not observed with the native IGFBP-1 promoter (Thulé et al, unpublished data) . Furthermore, a glucose-mediated impairment of insulin inhibition would be expected to produce a shift in insulin sensitivity, and this was not observed. The IC 50 for insulin suppression is the same in cells exposed to either lactate or glucose, and is similar to that reported for the native rIGFBP-1 promoter (Figure 4) . 20 Thus, the IRR and the GlRE function independently of one another. The fact that insulin inhibition in the (GlRE) n BP-1 system does not dominate the stimulatory effects of glucose on transgene expression is noteworthy, since stimulators of the native IGFBP-1 promoter are subordinate to the inhibitory effects of insulin. 26, 27 The concentration of glucose at which stimulation becomes measurable, resides within a range typical of normal rats, from 5 to 9 mm, and appears continuous through values commonly found in rats made diabetic by STZ administration. 28, 29 Moreover, stimulation increases continuously throughout the tested range of glucose concentrations (Figure 3) .
Whether transcriptional regulation is sufficient to provide acceptable fidelity between continuously changing metabolic requirements and insulin secretion in a gene therapy context is unknown. The fact that transcriptional regulation of insulin production cannot match the secretory dynamics of insulin from ␤ cells potentially limits the clinical utility of our system. Indeed, in normal individuals the importance of transcription on the shortterm regulation of insulin secretion is small relative to the effects of glucose on translation and post-translational processes. 30 However, insulin gene transcription within islets is highly regulated and stimulated by glucose. 31 In light of work demonstrating a five-fold increased abundance of insulin mRNA in islets within an hour following glucose exposure, the significance of glucose-stimulated transcription may warrant reappraisal. 32 Furthermore, the findings of Muzzin et al, 12 support the concept of utilizing transcription to regulate transgenic insulin production. Using a constitutive promoter to drive insulin production, they demonstrated that transcriptionally regulated insulin production can modify glycemia, while avoiding hypoglycemia during a short-term fast. 12 Thus, transcriptional responsiveness may be sufficient to improve the diabetic state dramatically. Our constructs increase protein synthesis in response to glucose in 1 h ( Figure 5) ; within the time-frame that subcutaneous insulin injection increases serum insulin concentrations. Moreover, experimental data suggest that hepatocytes may be capable of even more rapid responses. In their model of transcriptionally regulated insulin production from primary hepatocytes, Lu et al 11 report stimulated insulin secretion within 15 min following exposure to cAMP analogues. Similar results were obtained from a model of transcriptionally regulated insulin production in hepatoma cells. 33 Owing to an obligate time delay between stimulus and protein secretion unaugmented transcriptional regulation cannot produce physiologically responsive insulin levels. However, the use of transcription to control insulin production invites the addition of downstream regulatory mechanisms, in emulation of the multi-layered regulation observed in ␤ cells. 34 Most reported insulin gene therapy attempts have targeted the liver as a production site for transgenic insulin. 12, [15] [16] [17] [18] [19] 35 The liver commands a robust synthetic capacity and secretes large amounts of protein (eg albumin, coagulation factors and apo-lipoproteins) into the circulation. [36] [37] [38] However, their inability to process proinsulin has limited the utility of hepatocytes in insulin gene therapy. We have addressed this limitation by expressing a transgenic proinsulin accessible to cleavage by a hepatic endoprotease, furin. 9 Electrophoresis of radioactively labeled proteins from cells transfected with an insulinexpressing construct shows reduced and denatured bands with mobilities identical to those of insulin A-and B-chains ( Figure 6 ). Large amounts of processed insulin are probably not stored before secretion, since bands corresponding to mature insulin are not apparent in cell lysates. A band migrating at approximately 9.8 kb is consistent with the presence of proinsulin, 10 and the greater intensity of this band, compared with the bands for the A-and B-chains, suggests that the processing ability of these cells was exceeded. In spite of limited processing efficiency the quantity of secreted insulin is significant, Ͼ900 U insulin/approximately 3 × 10 6 hepatocytes/ 60 mm dish. Moreover, transgenic insulin secreted from hepatocytes produces an insulin-like biological effect. Medium conditioned by hepatocytes transfected with the modified proinsulin cDNA inhibits expression of an insulin-sensitive promoter-driven reporter gene (Figure 8 ). Reduced cell survival caused by insulin deficiency, coupled with nutrient depletion, could also diminish reporter expression. However, this fails to explain our results, since expression in control cells provided insulinfree medium conditioned by nontransfected hepatocytes was greater than under test conditions (Figure 8 ).
The capacity of our (GlRE) n BP-1 system to mediate transcriptionally regulated, glucose-responsive production of mature human insulin from hepatocytes is novel (Figure 9 ). Lu et al and others, have reported hepaGene Therapy tocyte-based insulin secretion that is responsive to stimulation by inducers of cAMP, or its analogues. 7, 11, 33 However, they were unable to obtain glucose stimulation utilizing GlRE elements from the L-PK gene, as we have done. 11 Their utilization of the ␤-actin promoter to drive insulin expression raises the possibility that GlRE sequences function poorly with this promoter. The IGFBP-1 promoter shares both a basic architecture and multiple transcription-factor binding domains with the L-PK promoter, 27, [39] [40] [41] and this similarity may be responsible for the greater than six-fold glucose stimulation observed in our studies (Figure 2) . Utilizing the carbohydrate-responsive promoter from the S14 gene, Wanke et al 42 reported glucose-responsive immunoreactive Cpeptide production from hepatocytes in primary culture. Their work suggests that other carbohydrate-responsive elements may prove useful as metabolic mediators of transgene expression. In addition to influencing transcription, glucose and insulin may affect other processes leading to insulin secretion from hepatocytes. Following stable transfection with the GLUT-2 glucose transporter, Simpson et al 8 reported a reversible glucose-stimulated insulin secretion from hepatoma cells, an effect probably mediated by vesicular release. However, clinical application was placed in question by subsequent findings that glucose responsiveness is lost when these hepatoma cells were transplanted into animals. 43 In addition to demonstrating a dose-response relationship between glucose and insulin production from hepatocytes (Figure 10 ), our studies also document reversibility of glucose stimulation in the (GlRE) 3 BP-1 system (Figure 11 ). The amount of immunoreactive insulin in medium conditioned by hepatoma cells stably transfected with the (GlRE) 3 BP-1 2xfur gene not only increased in response to glucose exposure, but declined following glucose withdrawal. Increased insulin production induced by re-provision of glucose suggests that the initial decline was a regulated response, and not due to cell death.
In conclusion, we have constructed a family of glucoseand insulin-sensitive promoters that function in primary cultured hepatocytes. Transcription of a reporter gene driven by these promoters is stimulated by glucose across a range of concentrations commonly found in subjects with diabetes. Expression is inhibited by insulin in the culture medium. However, this inhibition is independent of glucose-induced stimulation. When transfected with a human proinsulin cDNA, modified such that the A-C and C-B junctions encode furin cleavage sites, primary rat hepatocytes secrete fully processed, immunoreactive and biologically active human insulin. Combining a glucose-and insulin-sensitive promoter with the modified insulin cDNA produces a construct capable of mediating glucose inducible human insulin secretion from rat hepatocytes. Coupling of these constructs to a suitable vector delivery system will provide all components required to determine the behavior of these constructs in vivo, and to establish an animal model of insulin gene therapy.
Materials and methods
Promoter and viral constructs Base pairs − 324-+ 96 of the rat IGFBP-1 promoter were PCR amplified from p-930BPcat, 20 and the product ligated into a TA-cloning vector, pCRII (Invitrogen,
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Carlsbad, CA, USA). The primers were as follows, novel restriction sites (MluI in the forward primer, and NheI in the backward primer are underlined): forward; 5Ј-GCGACGCGTTCCCTTAGGTATTCCTTGAGTTCGG-3Ј, backward; 5Ј-GCGGCTAGCTAGTAGCGGAAGTGGT GGTTCACAG-3Ј. A 526 bp KpnI/XhoI restriction fragment was then directionally inserted into the luciferase expression vector, pGL2Basic (Promega, Madison, WI, USA), to create p − 324-+ 96BP-1Luc. The p(GlRE) n BP-1Luc plasmids were constructed by inserting copies of the glucose-responsive element from the rat L-PK gene into the IGFBP-1 promoter. Oligonucleotides corresponding to 50 bp of the positive (5Ј-CATGGGCGCACGGGGCA CTCCCGTGGTTCCTGGACTCTGGCCCCCAGTGTA-3Ј) and negative (5Ј-ATGTACACTGGGGGCCAGAGTCCA GGAACCACGGGAGTGCCCCGTGCG-CCC-3Ј) strands of the rat L-PK GlRE sequence were annealed, multimerized, and size fractionated by polyacrylamide electrophoresis. DNA representing a sequence of GlRE multimers, from one to four, was isolated from excised bands, and blunt-ended by treatment with Klenow. Insertion of GlRE multimers into EcoICRI restricted p Plasmids pLinkfurI.furII and pPEPCKfurI.furII, eukaryotic expression vectors, derived from pRK.proinsulin, carrying a modified human insulin cDNA allowing posttranslational processing of proinsulin by furin, were a gift of Dr Timothy Stewart, Genentech.
9 pCMV2xfur was constructed by replacing the PEPCK promoter of pPEPCKfurI.furII with the CMV immediate/early promoter/ enhancer. A NotI/HincII restriction fragment of pLinkfurI.furII containing the insulin expression sequence, was ligated into p(GlRE) 3 BP-1Luc constructs to produce p(GlRE) 3 BP-1 2xfur.
An adenoviral vector expressing human insulin, Ad/(G1RE) 3 BP-1 2xfur, was constructed using the Adeno-Quest kit per manufacturer's instructions (Quantum Biotechnologies, Montreal, Canada). A SalI/HincII fragment of p(GlRE) 3 BP-1 2xfur containing the glucose-and insulin-sensitive promoter coupled to the 2xfur sequence was inserted into the transfer vector pQBI-AdBN. Homologous recombination following cotransfection of pAdBN-(GlRE) 3 BP-1 2xfur and manufacturer-supplied viral DNA into HEK-293 cells permitted isolation of E1a/E1b/E3-deleted adenovirus containing the insulin transgene. We verified the capacity to induce insulin production by screening medium conditioned by primary cultured hepatocytes infected with crude lysates of expanded viral plaques using a human insulin-specific RIA (Linco Research, St Charles, MO, USA). Following three-fold plaque purification, viral preparations were purified by double CsCl density gradient centrifugation, dialyzed against 10% glycerol/HBS pH 7.4, aliquoted, and stored in this same buffer at −70°C. Viral concentration was determined by the tissue culture infectious dose method (TICD 50 ).
Sequencing
Sequencing of chimeric promoters was performed in the DNA Core Facility of Atlanta VA Medical Center/Emory University, using an Applied Biosystems Model 377 automated sequencer (Perkin Elmer, Foster City, CA, USA).
Cell culture and transfection
Hepatocytes were isolated from male Sprague-Dawley rats (150 to 200 g, Charles Rivers Laboratories, Wilmington, MA, USA) by a modification of the collagenase (Worthington, Freehold, NJ, USA) perfusion method of Seglen. 44 Briefly, following anesthesia by intraperitoneal injection of a ketamine/xylazine mixture, the portal vein was canulated with a 20 gauge venous catheter, and the liver perfused with collagenase-buffer for 6 min. Livers were removed en masse, and the cells gently shaken from the perforated hepatic capsule in DMEM/F12 (Mediatech Cellgro, Herndon, VA, USA) supplemented with 10% fetal calf serum (FCS) (Atlanta Biological, Marietta, GA, USA). Hepatocytes (3.5-5 × 10 6 cells) were added to 60 mm plates (Falcon/Becton Dickinson Labware, Lincoln Park, NJ, USA) coated with rat tail collagen (Sigma, St Louis, MO, USA), and non-adherent cells removed 20 min later. Incubations were performed in an atmosphere of 95% air, 5% CO 2 at 37°C. Transient transfection (5 g of test construct and 0.1 or 0.2 g pCMV␤-gal per plate as a control for transfection efficiency) was performed overnight in 3% FCS/DMEM/F12 using a DNA/CaPO 4 co-precipitation method, modified from Ginot et al. 45 Plasmid DNA was isolated by twice banding over a CsCl gradient, followed by extensive dialysis against TE buffer. Hepatocyte response to glucose was evaluated by providing serum-free DMEM/F12 medium (JRH Biosciences, Lenexa, KS, USA) custom blended without glucose, to which glucose or L(+)-lactate were subsequently added. To control for osmotic forces, carbohydrate concentration was maintained by substituting equimolar amounts of L(+)-lactate for glucose, up to 10 mm. Reconstituted, defined medium contained amino acids at 20× concentration of rat arterial plasma, dexamethasone 10 −7 m (Sigma), PCN/Strep (100 U/ml PCN, 100 g/ml streptomycin) (Sigma), human apo-transferrin 0.01 mg/ml (Sigma), and fatty acid-free, bovine serum albumin 1 mg/ml (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA). Bovine insulin (GibcoBRL, Gaithersburg, MD, USA), was added from a sterile filtered, 10 −4 m stock, dissolved in 0.1 m HCl. D+Glucose was added from a 140 mg/ml sterile filtered stock solution. L(+)-lactate (Sigma) was dissolved into defined medium just before addition to cells. Stable transfection was performed as described. 46 Briefly, 70% confluent H4IIE cells (a generous gift of Dr John Koontz, University of Tennessee) were cotransfected with p(GlRE) 3 BP-12xfur (2 g/60 mm plate) and pRcCMV/Neo (Invitrogen, Carlsbad, CA, USA) (2 g/60 mm plate), using the adenovirus/polyethylenimine/DNA-conjugate method. 47 Colonies were isolated under selection in G418 (0.3 mg/ml) (GibcoBRL), and screened for human insulin production by human insulin-specific RIA (Linco) of conditioned medium. An insulin secreting cell line, designated A3, was utilized to document glucose-dependent insulin secretion. Two groups of A3 cells expanded to 80% confluence in triplicate wells of collagen coated, sixwell plates were washed twice with PBS to remove traces of serum. Thereafter, cells were alternated between medium containing either 10 mm L(+)-lactate, or 10 mm glucose every 2 days, for 8 days. Culture medium was changed daily. One group was initially provided lactate. The other group initially received glucose. Cells were washed every second day to minimize mechanical stimulation, while reducing carry-over contamination, and conditioned medium was collected just before each wash.
Reporter assays
Luciferase assays were performed using the Luciferase Reporter Assay System (Promega, Madison, WI, USA). Twenty microliters of cell lysate, created by adding 250 l of Reporter Lysis Buffer (Promega) per 60 mm plate, was combined with 100 l of Luciferase Assay Buffer per well of a 96-well plate. Emitted light was measured for 20 s at ambient temperature in a Model ML 3000 plate reading luminometer (Dynatech, Chantilly, VA, USA). ␤-Galactosidase assays were performed using the same instrument. However, for these assays 10 l of lysate were combined with 100 l of Lumigal (Lumigen, Detroit, MI, USA), and emitted light measured for 10 s at 37°C.
Protein labeling
Protein labeling using 35 S-methionine/cysteine was performed essentially as described by Marriott et al. 48 Freshly plated primary hepatocytes were transfected by Ca/PO 4 DNA co-precipitation, and cultured overnight in 3% FCS/DMEM/F12 (Mediatech Cellgro). Cells were washed twice in 1× PBS, and provided a methionine/ cysteine-depleted medium (JRH Biosciences) for 2 h before addition of 4 mCi of 35 S-methionine/cysteine (Promix; Amersham/Pharmacia Biotech, Arlington Heights, IL, USA) per 100 mm plate. Cultures were continued for either 4 h or overnight and conditioned medium collected. Cells were washed twice and collected in 1× PBS, before lysis via three cycles of freeze-thaw. Conditioned media and cell lysates were immunoprecipitated with human insulin-specific anti-serum (Linco Research, St Charles, MO), and Protein-A-Sepharose CL-4B (Pharmacia Biotech). Immune complexes were subjected to denaturing SDS-PAGE using an 18% polyacrylamide separating gel, and a 4% stacking gel. MESNA (2-mercaptoethanesulfonic acid) (0.4 m) (Sigma) was included in the loading buffer to ensure complete reduction of disulfide bonds. A commercial polypeptide standard, which included the bovine insulin B-chain, and 125 I-labeled human insulin, mono-iodinated on the A-chain (Linco Research), were included as positive controls for the B and A chains, respectively. After drying overnight, gels were exposed for 2-4 days, and detected using a phosphor-imager (Molecular Dynamics Sunnyvale, CA, USA).
Insulin in conditioned medium was measured using either a dual monoclonal antibody Microparticle Enzyme Immunoassay (MEIa) (IMx Insulin, Abbott Diagnostics, Abbott Park, II, USA), or a standard anti-human insulin RIA kit (Linco Research). The manufacturer of the dual monoclonal antibody MEIa reports the dynamic range as 1-300 U/ml, the sensitivity as greater than 1.0 U/ml, the cross-reactivity with human proinsulin = 0.005%, within assay CVs of 4.0%, between assay coefficient of variation 4.5%, and total run coefficient of variation of 6.0%, at a mean concentration of 8.3 U/ml. The standard RIA kit is reported to have cross-reactivities of human proinsulin Ͻ0.2%, Des 31,32 insulin Ͻ0.2% Des Gene Therapy 64,65 insulin = 76%, rat insulin Ͻ1.0%. Each was used according to the manufacturers' instructions.
Northern analysis
Ten micrograms of total RNA per lane, isolated from transduced primary hepatocytes using TRIzol Reagent (GibcoBRL/Life Technologies), was electrophoresed on a 1% agarose-7% formaldehyde gel. Following capillary transfer and UV cross-linking to a nylon membrane (Hybond-N, Amersham/Pharmacia Biotech), blots were pre-hybridized, and hybridized at 68°C using QuikHyb (Stratagene, La Jolla, CA, USA), and washed for 30 min at 68°C with a 0.1% SSC/0.1% SDS solution. Images were developed, and quantified using a phosphor-imager with accompanying densitometry software (Molecular Dynamics). Following initial analysis using a human insulin probe, membranes were stripped and re-probed using a human GAPDH sequence. Probes were labeled using random priming (Prime-It II; Stratagene, La Jolla, CA, USA) of plasmid restriction fragments derived from either pLinkIfurIIfur for insulin, or pBShGAPDH for GAPDH (a kind gift from Dr Maria Alexander-Bridges, Howard Hughes Medical Institute, Massachusetts General Hospital, Boston, MA).
Statistics
Means and standard errors of the mean were calculated using programs resident in either Sigma Plot v. 3.2, or Excel 97. P values were calculated using a one-tailed t test, assuming unequal variances.
